Walter Fiedler

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7312572/publications.pdf

Version: 2024-02-01

202 papers	12,068 citations	38742 50 h-index	28297 105 g-index
208 all docs	208 docs citations	208 times ranked	13013 citing authors

#	Article	IF	Citations
1	COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies. Leukemia and Lymphoma, 2022, 63, 664-671.	1.3	4
2	Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemiaâ€"A Single Center Analysis. Antibiotics, 2022, 11, 128.	3.7	2
3	Impact of Venetoclax and Azacitidine in Treatment-NaÃ¯ve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clinical Cancer Research, 2022, 28, 2753-2761.	7.0	70
4	Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by Î³Î´ T Cells in Ovarian Cancer. Cells, 2022, 11, 964.	4.1	19
5	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer Journal, 2022, 12, 71.	6.2	12
6	Donorâ€transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation. British Journal of Haematology, 2022, , .	2.5	1
7	Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Advances, 2022, 6, 5345-5355.	5.2	24
8	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, .	4.1	5
9	Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment. Cancers, 2022, 14, 2773.	3.7	1
10	Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine. Leukemia and Lymphoma, 2022, 63, 2645-2651.	1.3	2
11	Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, highâ€dose cytarabine and mitoxantrone. British Journal of Haematology, 2021, 192, e60-e63.	2.5	3
12	Newly diagnosed isolated myeloid sarcomaâ€"paired NGS panel analysis of extramedullary tumor and bone marrow. Annals of Hematology, 2021, 100, 499-503.	1.8	9
13	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology, 2021, 100, 1181-1194.	1.8	27
14	Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Scientific Reports, 2021, 11, 5803.	3.3	40
15	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Advances, 2021, 5, 2294-2304.	5.2	60
16	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica, 2021, 106, 2986-2989.	3.5	5
17	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. Journal of Clinical Medicine, 2021, 10, 2274.	2.4	19
18	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. IScience, 2021, 24, 102752.	4.1	9

#	Article	IF	Citations
19	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	1.4	91
20	High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells. Frontiers in Immunology, 2021, 12, 675731.	4.8	15
21	Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin. Annals of Hematology, 2021, 100, 2727-2732.	1.8	8
22	The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia. Annals of Hematology, 2021, 100, 2933-2941.	1.8	5
23	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. HemaSphere, 2021, 5, e617.	2.7	10
24	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. Blood Advances, 2021, 5, 4370-4379.	5.2	5
25	6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer Journal, 2021, 11, 163.	6.2	17
26	Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 10670.	4.1	6
27	Bone Marrow-Resident VÎ´1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma. Frontiers in Medicine, 2021, 8, 763773.	2.6	21
28	Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. International Journal of Molecular Sciences, 2021, 22, 12919.	4.1	27
29	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. Blood, 2021, 138, 692-692.	1.4	1
30	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia, 2020, 34, 914-918.	7.2	46
31	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. Journal of Clinical Oncology, 2020, 38, 623-632.	1.6	73
32	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology, 2020, 13, 92.	17.0	28
33	Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity. Frontiers in Immunology, 2020, 11, 580557.	4.8	50
34	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	7.2	38
35	Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 5084.	4.1	15
36	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood, 2020, 136, 3041-3050.	1.4	73

#	Article	IF	Citations
37	Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients. Blood Advances, 2020, 4, 5936-5941.	5.2	16
38	Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg. Oncology Research and Treatment, 2020, 43, 307-313.	1.2	32
39	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology, 2020, 190, e169-e173.	2.5	14
40	The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies. Expert Opinion on Therapeutic Targets, 2020, 24, 451-462.	3.4	11
41	Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis. Cancers, 2020, 12, 1678.	3.7	3
42	Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. International Journal of Molecular Sciences, 2020, 21, 602.	4.1	15
43	Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients. Pharmacotherapy, 2020, 40, 479-483.	2.6	3
44	Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood, 2020, 135, 2137-2145.	1.4	470
45	Transforming growth factor beta type 1 (TGF-Î²) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells. Aging, 2020, 12, 23478-23496.	3.1	26
46	Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA). Blood, 2020, 136, 39-40.	1.4	6
47	Increased Frequency of TOX+ CD39+ TIGIT+ CD73- CD8+ T Cells in Patients with Newly Diagnosed AML. Blood, 2020, 136, 36-36.	1.4	0
48	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). Blood, 2020, 136, 42-42.	1.4	0
49	Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols. Blood, 2020, 136, 37-38.	1.4	4
50	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. Blood, 2020, 136, 33-35.	1.4	1
51	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. OncoImmunology, 2019, 8, e1674605.	4.6	59
52	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood, 2019, 134, 1608-1618.	1.4	85
53	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology, 2019, 37, 1277-1284.	1.6	494
54	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. Cancers, 2019, 11, 1663.	3.7	10

#	Article	IF	Citations
55	Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. Haematologica, 2019, 104, e63-e64.	3.5	4
56	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 2019, 33, 379-389.	7.2	396
57	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood, 2019, 133, 840-851.	1.4	228
58	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 583-587.	2.5	5
59	Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. British Journal of Haematology, 2019, 185, 595-598.	2.5	19
60	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open, 2018, 3, e000303.	4.5	12
61	High mobility group box 1 (HMGB1) acts as an â€œalarminâ€• to promote acute myeloid leukaemia progression. OncoImmunology, 2018, 7, e1438109.	4.6	34
62	Acute hepatitis as a prequel to very severe aplastic anemia. Zeitschrift Fur Gastroenterologie, 2018, 56, 51-54.	0.5	4
63	Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates. Nanoscale, 2018, 10, 5827-5833.	5.6	19
64	A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTEÂ®) antibody construct, in patients with refractory solid tumors. OncoImmunology, 2018, 7, e1450710.	4.6	111
65	Phase I/<scp>II</scp> study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (<scp>AMLSG</scp> 17â€10 <scp>CIARA</scp> trial). British Journal of Haematology, 2018, 183, 235-241.	2.5	2
66	Acute Myeloid Leukemia and the Bone Marrow Nicheâ€”Take a Closer Look. Frontiers in Oncology, 2018, 8, 444.	2.8	66
67	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, 2018, 132, 1703-1713.	1.4	237
68	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene, 2018, 37, 5269-5280.	5.9	65
69	Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open, 2018, 3, e000381.	4.5	10
70	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemiaâ€”results of the AMLSG 11-08 trial. Leukemia, 2018, 32, 1621-1630.	7.2	81
71	Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. Mammalian Genome, 2018, 29, 694-702.	2.2	29
72	Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression. Cellular and Molecular Immunology, 2018, 15, 994-997.	10.5	9

#	Article	IF	Citations
73	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. Blood, 2018, 132, 1501-1501.	1.4	3
74	Mebendazole Exerts Potent Anti-Leukemic Effects By Downregulating Protein Levels of Hedgehog Transcription Factors GLI1 and GLI2. Blood, 2018, 132, 5145-5145.	1.4	1
75	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology, 2017, 96, 895-904.	1.8	7
76	The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells. EBioMedicine, 2017, 22, 44-57.	6.1	167
77	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Nonâ€"High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Journal of Clinical Oncology, 2017, 35, 605-612.	1.6	299
78	Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. Oncotarget, 2017, 8, 29187-29201.	1.8	28
79	Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia. Translational Cancer Research, 2017, 6, S286-S291.	1.0	0
80	Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone. Journal of Surgical Oncology, 2016, 113, 515-521.	1.7	9
81	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. Haematologica, 2016, 101, 839-845.	3.5	22
82	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Annals of Hematology, 2016, 95, 1931-1942.	1.8	61
83	A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. European Journal of Cancer, 2016, 63, 55-63.	2.8	57
84	Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia. European Journal of Haematology, 2016, 97, 239-244.	2.2	9
85	Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature. Molecular and Clinical Oncology, 2016, 4, 390-392.	1.0	7
86	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged â‰¥65 Years with Acute Myeloid Leukemia. Blood, 2016, 128, 102-102.	1.4	40
87	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). Blood, 2016, 128, 1207-1207.	1.4	10
88	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. Blood, 2016, 128, 337-337.	1.4	5
89	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. Blood, 2016, 128, 449-449.	1.4	18
90	BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles. Blood, 2016, 128, 592-592.	1.4	1

#	Article	IF	Citations
91	Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age â‰¥ 65 with acute myelogenous leukemia.. Journal of Clinical Oncology, 2016, 34, 7007-7007.	1.6	22
92	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget, 2016, 7, 32532-32542.	1.8	75
93	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. Blood, 2016, 128, 1662-1662.	1.4	0
94	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2015, 100, e122-e124.	3.5	20
95	Thrombin generation in a patient with an acquired high-titre factor V inhibitor. Blood Coagulation and Fibrinolysis, 2015, 26, 81-87.	1.0	3
96	Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clinical Cancer Research, 2015, 21, 2388-2398.	7.0	88
97	Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension. Lung, 2015, 193, 567-570.	3.3	16
98	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. British Journal of Haematology, 2015, 169, 694-700.	2.5	90
99	ErbB2 signaling activates the Hedgehog pathway via PI3Kâ€“Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts. Cellular Signalling, 2015, 27, 373-381.	3.6	45
100	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). Blood, 2015, 126, 226-226.	1.4	4
101	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2586-2586.	1.4	1
102	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). Blood, 2015, 126, 322-322.	1.4	32
103	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. Blood, 2015, 126, 3789-3789.	1.4	3
104	Expression and Release of Platelet Protein Disulfide (PDI) Isomerase Is Increased in Patients with Hemophilia a. Blood, 2015, 126, 1085-1085.	1.4	0
105	New Antiangiogenic Strategies beyond Inhibition of Vascular Endothelial Growth Factor with Special Focus on Axon Guidance Molecules. Oncology, 2014, 86, 46-52.	1.9	18
106	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncology, 2014, 10, 1157-1165.	2.4	22
107	Contribution of the vascular bone marrow niche to leukemia progression. Memo - Magazine of European Medical Oncology, 2014, 7, 198-201.	0.5	1
108	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood, 2014, 124, 1426-1433.	1.4	204

#	Article	IF	Citations
109	Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection. PLoS ONE, 2014, 9, e104742.	2.5	13
110	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). Blood, 2014, 124, 1254-1254.	1.4	0
111	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts <10G/L. Blood, 2014, 124, 2636-2636.	1.4	0
112	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 111-121.	27.0	1,284
113	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Annals of Hematology, 2013, 92, 315-323.	1.8	48
114	Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway. Molecular Cancer, 2013, 12, 144.	19.2	12
115	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood, 2013, 122, 2443-2452.	1.4	178
116	Acute Megakaryoblastic Leukemia in a Patient with Xeroderma Pigmentosum: Discussion of Pathophysiological, Prognostic, and Toxicological Aspects. Acta Haematologica, 2013, 129, 121-125.	1.4	6
117	Late Recurrence of a Pineal Germinoma 14 Years after Radiation and Chemotherapy: A Case Report and Review of the Literature. Onkologie, 2013, 36, 371-373.	0.8	3
118	Chylothorax in a Patient with Hodgkin's Lymphoma: A Case Report and Review of the Literature. Tumori, 2013, 99, e96-e99.	1.1	14
119	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. Blood, 2013, 122, 2555-2555.	1.4	0
120	Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature. Tumori, 2013, 99, e96-9.	1.1	9
121	Critical Imbalance of TNF-Î± and Soluble TNF Receptor 1 in a Patient with Macrophage Activation Syndrome: Potential Implications for Diagnostics and Treatment. Acta Haematologica, 2012, 128, 69-72.	1.4	24
122	CD146: a new partner for VEGFR2. Blood, 2012, 120, 2164-2165.	1.4	6
123	VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. Clinical and Experimental Metastasis, 2012, 29, 879-887.	3.3	7
124	The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature. Cancer Letters, 2012, 326, 161-167.	7.2	3
125	Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment. Blood, 2012, 120, 411-411.	1.4	10
126	Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 433-438.	0.4	50

#	Article	IF	Citations
127	Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients. European Journal of Radiology, 2011, 80, 655-661.	2.6	6
128	Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 2889-2896.	1.6	351
129	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood, 2011, 117, 4561-4568.	1.4	99
130	Primary tumor dependent inhibition of tumor growth, angiogenesis, and perfusion of secondary breast cancer in bone. Journal of Orthopaedic Research, 2011, 29, 1251-1258.	2.3	15
131	Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase. Anti-Cancer Agents in Medicinal Chemistry, 2011, 11, 593-599.	1.7	45
132	Prognostic Importance of Histone MethyltransferaseMLL5Expression in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 682-689.	1.6	53
133	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. Cancer Research, 2011, 71, 1362-1373.	0.9	117
134	A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). Acta OncolÃ³gica, 2011, 50, 121-126.	1.8	36
135	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2010, 116, 614-616.	1.4	170
136	Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer. Expert Opinion on Investigational Drugs, 2010, 19, 777-788.	4.1	91
137	TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis. Investigational New Drugs, 2010, 28, 825-833.	2.6	34
138	Microcirculation of secondary bone tumors in vivo: The impact of minor surgery at a distal site. Journal of Orthopaedic Research, 2010, 28, 1515-1521.	2.3	13
139	An open-label, Phase I study of cediranib (RECENTINâ„¢) in patients with acute myeloid leukemia. Leukemia Research, 2010, 34, 196-202.	0.8	40
140	Homogeneous EGFR amplification defines a subset of aggressive Barrettâ€™s adenocarcinomas with poor prognosis. Histopathology, 2010, 57, 418-426.	2.9	30
141	TGF-Î² Superfamily Receptorsâ€”Targets for Antiangiogenic Therapy?. Journal of Oncology, 2010, 2010, 1-10.	1.3	15
142	Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041). Clinical Cancer Research, 2010, 16, 1315-1323.	7.0	39
143	Isolated Limb Perfusion with Melphalan for the Treatment of Intractable Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. Acta Haematologica, 2010, 123, 179-181.	1.4	16
144	Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 578-585.	1.6	119

#	Article	IF	Citations
145	FLT3 - ITD positive acute lymphocytic leukemia, does it impact on diseaseÂ´s course?. Turkish Journal of Haematology, 2010, 27, 133-134.	0.5	1
146	Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. Journal of Clinical Oncology, 2010, 28, 2356-2364.	1.6	229
147	Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology, 2010, 41, 1577-1585.	2.0	79
148	Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 551-558.	1.3	16
149	Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2009, 27, 6152-6159.	1.6	96
150	PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Leukemia Research, 2008, 32, 1857-1865.	0.8	18
151	Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative. British Journal of Haematology, 2008, 142, 115-118.	2.5	21
152	Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. Journal of Experimental and Clinical Cancer Research, 2008, 27, 86.	8.6	89
153	Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood, 2008, 111, 4355-4364.	1.4	163
154	Determination of Microvessel Density by Quantitative Real-time PCR in Esophageal Cancer: Correlation with Histologic Methods, Angiogenic Growth Factor Expression, and Lymph Node Metastasis. Clinical Cancer Research, 2007, 13, 76-80.	7.0	44
155	Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma. Oncology Research and Treatment, 2007, 30, 519-524.	1.2	24
156	CFU-EC: how they were originally defined. Blood, 2007, 110, 1073-1073.	1.4	12
157	Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochemical and Biophysical Research Communications, 2007, 357, 1016-1020.	2.1	31
158	An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 895-895.	1.4	0
159	Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leukemia and Lymphoma, 2006, 47, 2601-2609.	1.3	25
160	Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activatingRASmutations. Leukemia and Lymphoma, 2006, 47, 1387-1391.	1.3	10
161	Quantitative multiplexed profiling of cellular signaling networks using phosphotyrosine-specific DNA-tagged SH2 domains. Nature Methods, 2006, 3, 737-744.	19.0	31
162	Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 433-433.	1.4	6

#	Article	IF	Citations
163	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. Blood, 2006, 108, 1949-1949.	1.4	1
164	Identification of Circulating Lymphendothelial Cells in the Blood of Patients with Solid Tumors.. Blood, 2006, 108, 3947-3947.	1.4	0
165	Prospective Randomized Comparison of High Dose AraC and AutoPBSCT as Late Consolidation for Patients â‰¤60 Years with Standard Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial.. Blood, 2006, 108, 607-607.	1.4	0
166	Cilengitide Inhibits Proliferation and Differentiation of Human Endothelial Progenitor Cells In Vitro.. Blood, 2006, 108, 3929-3929.	1.4	0
167	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 2005, 105, 986-993.	1.4	481
168	Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood, 2005, 106, 3958-3961.	1.4	79
169	Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor for Overall Survival. Journal of Clinical Oncology, 2005, 23, 1109-1117.	1.6	97
170	Difficult Diagnostic Cases. Journal of Clinical Oncology, 2005, 23, 3624-3626.	1.6	23
171	Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. European Journal of Cancer, 2005, 41, 1073-1085.	2.8	17
172	Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 2005, 50, 51-58.	2.0	38
173	Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.. Blood, 2005, 106, 172-172.	1.4	17
174	Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients â‰¤60 Years with Standard Risk AML.. Blood, 2005, 106, 151-151.	1.4	0
175	An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thrombosis and Haemostasis, 2004, 92, 1136-1146.	3.4	25
176	Identification of the Adult Human Hemangioblast. Stem Cells and Development, 2004, 13, 229-242.	2.1	77
177	Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Experimental Cell Research, 2004, 300, 65-71.	2.6	91
178	Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.. Blood, 2004, 104, 145-145.	1.4	6
179	Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.. Blood, 2004, 104, 618-618.	1.4	2
180	A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 2003, 102, 2763-2767.	1.4	262

#	Article	IF	Citations
181	An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical Cancer Research, 2003, 9, 5465-76.	7.0	242
182	Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer, 2002, 36, 303-307.	2.0	18
183	A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer. Oncology Reports, 2001, 8, 225.	2.6	1
184	Effects of Vascular Endothelial and Platelet-derived Growth Factor Receptor Inhibitors on Long-term Cultures from Normal Human Bone Marrow. Growth Factors, 2001, 19, 1-17.	1.7	18
185	Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood, 2001, 98, 241-243.	1.4	131
186	Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis, 2001, 4, 193-206.	7.2	71
187	Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome. , 2000, 88, 344-351.		34
188	Author reply. Cancer, 2000, 89, 222-223.	4.1	1
189	In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 2000, 95, 3106-3112.	1.4	944
190	Sensitivity of Assays Designed for the Detection of Disseminated Epithelial Tumor Cells Is Influenced by Cell Separation Methods. Clinical Chemistry, 2000, 46, 435-436.	3.2	16
191	Angiogenic switch and vascular stability in human Leydig cell tumours. Angiogenesis, 1999, 3, 231-240.	7.2	9
192	Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. Journal of Cancer Research and Clinical Oncology, 1999, 125, 621-629.	2.5	82
193	Antimycotic Therapy with Liposomal Amphotericin-B for Patients Undergoing Bone Marrow or Peripheral Blood Stem Cell Transplantation. Leukemia and Lymphoma, 1997, 24, 491-499.	1.3	14
194	Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia. Blood, 1997, 89, 1870-1875.	1.4	417
195	Karyotype in multiple myeloma and plasma cell leukaemia. European Journal of Cancer, 1993, 29, 1269-1273.	2.8	82
196	GCSF gene is expressed but not rearranged in a patient with isochromosome 17q positive acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 1993, 68, 49-51.	1.0	7
197	A pilot study of recombinant human TNF and interferonâ€gamma in four patients with refractory AML. European Journal of Haematology, 1992, 48, 115-116.	2.2	0
198	Mitoxantrone/high-dose ara-c and recombinant human gm-csf in the treatment of refractory non-hodgkin's lymphoma a pilot study. Cancer, 1990, 66, 423-430.	4.1	46

#	Article	IF	Citations
199	Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin study group. Cancer, 1990, 66, 838-843.	4.1	13
200	Immunophenotype of Abnormal Metaphases Demonstrating Multilineage Involvement in Myelodysplastic Syndromes. Leukemia and Lymphoma, 1990, 2, 201-205.	1.3	2
201	GMâ€CSF in busulfan overdosage. European Journal of Haematology, 1990, 45, 183-184.	2.2	5
202	T-cell activation defect in common variable immunodeficiency: Restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clinical Immunology and Immunopathology, 1987, 44, 206-218.	2.0	37